Skip to content

#Psilocybin

5 NovThu
4 NovWed
2 NovMon
  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.

30 OctFri
  1. Europe PMC: new psychedelic research papers55

    Psilocybin with psychological support for anhedonia in treatment-resistant depression: a randomised controlled pilot trial

    A randomised, double-blind, placebo-controlled pilot trial in 20 participants with treatment-resistant major depressive disorder found no statistically significant between-group difference in anhedonia at the primary week 1 endpoint, with a DARS change difference of 11.2 (95% CI, -1.0 to 23.3; p = 0.073) for psilocybin 25 mg versus 1 mg, both given with psychological support.

19 SepSat
  1. Europe PMC: new psychedelic research papers52

    Review examines psychedelics and suicidality as a double-edged sword

    A review examines the relationship between classic psychedelics such as LSD, psilocybin and DMT and suicidality, proposing a theoretical double-edged sword model. The authors report that several deaths followed non-medical psychedelic use in unsafe contexts, with unclear suicidal intent, and that rare cases of increased suicidal ideation and behaviours in clinical settings showed no significant differences from placebo groups or established causality.

8 JunMon
  1. TGA: interim scheduling decisions (Australia)62

    TGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40

    The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.

    Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.

28 MayThu
17 Dec 2025Wed
  1. TGA: interim scheduling decisions (Australia)58

    TGA publishes interim decisions on proposed Poisons Standard amendments from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.